- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr C. Noel Bairey Merz Discusses ESCaPE-CMD Phase 2 Study Results of Patients With CMD
The phase 2 ESCaPE-CMD study results exhibited a significant improvement in coronary flow reserve for patients with CMD, said C. Noel Bairey Merz, MD, FACC, FAHA, director of the Barbra Streisand Women's Heart Center.
The phase 2 ESCaPE-CMD study results exhibited a significant improvement in coronary flow reserve for patients with CMD, said C. Noel Bairey Merz, MD, FACC, FAHA, director of the Barbra Streisand Women's Heart Center.
Transcript
Can you describe the primary endpoint of the ESCaPE-CMD trial and how positive results were obtained through the CLBS16 treatment?
The trial name is actually ESCaPE-CMD coronary microvascular dysfunction. The primary outcome was invasively measured intracoronary adenosine coronary flow reserve, a rigorous method which we have demonstrated previously as quite reproducible without change in other placebo control trials. What the outcome demonstrated in this trial was an amine score for the group of 20 subjects of 2.0. So, very abnormal coronary flow reserve in these microvascular angina patients improved to a mean of 2.6, a very significant improvement and much better than what we have achieved with other placebo-controlled trials such as ACE inhibitors or high intensity statins.
What impact has CD34 cell therapy had on microvascular function for patients with CMD?
We found in this phase 1, 2 pilot trial of 20 subjects, open label, that the CD34 cells had a quite dramatic effect on invasively measured coronary flow reserve. The average was 2—went up to 2.6, meaning the average patient normalized, and that this was permanent or persistent through a 6-month follow up. A number of patients became angina free.
What do the study results presented at AHA 2019 reveal about the impact of CLBS16 on CMD?
Based on the clinical coronary flow reserve data, these suggest that this will be an effective therapy for coronary microvascular dysfunction patients. Needless to say, this was open label, so we cannot discount a placebo effect—perhaps in the Seattle Angina Questionnaire scores; but the rigor of an objectively measured coronary flow reserve, which we’ve demonstrated previously changes very little with a placebo in other trials that we’ve done, suggest that this may be a beneficial therapy which requires further definitive testing.
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Ways Providers, Payers Can Ensure Biomarker Testing Is Done in Cancer Care
October 18th 2024There is a role for both payers and providers to make small changes that would increase the use of biomarker testing to ensure patients are receiving the appropriate treatment, said Susan Wescott, RPh, MBA, senior director of managed care pharmacy, Mayo Clinic.
Read More
